This article summarized the latest R&D progress of Ropinirole, Mechanism of Action for Ropinirole and drug target for Ropinirole.

This is the first and only RSV vaccine for pregnant women, marking an important milestone for public health.

We wait to see who will become the next drug king in the GLP-1 race.

Lotilaner (Xdemvy), a small molecule drug that targets GluCls, was developed by Tarsus Pharma-ceuticals, Inc. and received FDA approval on July 24th, 2023 for the treatment of demodex blepharitis.

FCN-159 is an orally effective selective MEK1/2 inhibitor and a prospective targeted therapy drug for tumors mutated by BRAF or RAS.

Zenocutuzumab is a bispecific antibody targeting HER2/HER3 developed by Merus NV. On July 7, 2023, the U.S. FDA granted Zenocutuzumab breakthrough therapy desig-nation for NRG1 fusion-positive non-small cell lung cancer.

Selinexor, a small molecule drug targeting XPO1, is developed by Karyopharm Therapeutics, Inc.

Lanifibranor, a small-molecule drug targeting PPARα + PPARγ + PPARδ, was initially developed by AbbVie, Inc.

Brogidirsen is a drug targeting DMD exon 44 antisense oligonucleotide, developed by Nippon Shinyaku Co.

Fruquintinib is a small molecule drug targeting VEGFR1, VEGFR2, and VEGFR3. This drug was initially developed by Hutchison Whampoa Medicine (Shanghai) Co., Ltd.

Anthrax Vaccine Adsorbed, Adjuvanted, com-mercially known as CYFENDUS, is a preventive vaccine targeting TLR9.

the approved dose for BMS's Deucravacitinib treatment of psoriasis is 6mg QD, whereas the estimated dose for TAK279 clinical treatment of psoriasis is over 30mg QD. Why does TAK279 have BIC potential?